Sanofi faces $250M charge after E. coli vaccine developed with J&J fails Phase 3 trial; study ends early due to insufficient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback